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 There are different treatment modalities for common warts and all of them have side 
effects. Niosomal drug delivery systems have increased efficacy by enhanced transport of 
therapeutic agents through stratum corneum with decreased side effects. In this study, we assessed 
the efficacy of combined 2% niosomal zinc sulfate cream plus cryotherapy compared with 
combination of placebo plus cryotherapy. 
 Sixty patients with verruca vulgaris enrolled in this randomized clinical trial study. 
Patients were divided in 2 groups. Group A received 2% niosomal zinc sulfate cream and group B 
received placebo twice a day. Also, patients in both groups were treated with cryotherapy (liquid 
nitrogen) every other week. Treatment protocols continued for a maximum of 3 months or until total 
clearance of the lesions. 
 Mean number of the sessions for complete remission was 4.5±1.38 in group A and 
5.36±0.88 in group B and the difference between the two groups was statistically significant. 
Complete remission was observed in 60% in group A compared with 43.3% in group B that was not 
statistically significant. 
 Combination therapy with niosomal zinc plus cryotherapy can lead to faster and 
greater percentage clearance of the lesions without significant increase in adverse effects in 
comparison with cryotherapy plus placebo.  
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Introduction 
Common wart is a common skin disease caused by 
various types of human papilloma virus (HPV) that can 
develop at any age being most prevalent in children and adult 
(1,2). In one study in Kerman the prevalence of common wart 
in school boy children was estimated to be about 15.26% (3). 
Lesions may clear without any treatment probably taking 
months to years (4). Development of the lesions especially in 
exposed sites and in large numbers can affect physical 
appearance and decrease the quality of patients’ lives. Rarely, 
long-lasting untreated lesions can progress to premalignant 
and malignant lesions (5). 
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Today, there is no specific treatment for HPV. Choice of 
treatment modality depends on site and size of involvement, 
age and immune status of the patients. Treatments are 
classified to cytotoxic and immunomodulatory drugs, as well 
as ablative methods (2). 
Cryotherapy is the first line treatment for common warts 
that leads to necrosis and cell death plus stimulation of 
immune system against HPV. Efficacy of cryotherapy in 
clinical trials is varied between 9 to 87 % (mean 49%) based 
on treatment intervals and each cycle duration of the freeze. 
Disadvantages of this method include frequent sessions of 
expensive therapy that takes a lot of time and days off with 
pain, probable blister and scar formation. Also, application of 
cryotherapy near nerves, tendons and nails and in persons with 
poor blood circulation needs caution (6). 
Zinc sulfate as intralesional or topical formulation is 
another treatment for common warts. Although it has a good 
efficacy, side effects including severe pain of injection, 
erythema, swelling and risk of necrosis may limit its use (7). 
Niosomes are new vesicular systems ranging in size from 
nanometer to micron composing nonionic surfactants and 
cholesterol. Since these niosomal systems have better drug 
penetration through biological membranes with reduced 
adverse effects, so for the first time we decided to evaluate the 
efficacy of combination of 2% niosomal zinc sulfate cream 
plus cryotherapy in comparison with placebo plus cryotherapy 
(8,9). 
 
Materials and methods: 
We obtained Sorbitan monostearate (Span
TM
 60), zinc 
sulfate heptahydrate (ZnSO4.7H2O) and cholesterol from 
Merck, Germany. All other chemicals and solvents were in 
analytical grade and obtained from Merck, Germany, too.  
 
Niosome preparation 
Non-ionic surfactant vesicles (niosomes) were prepared 
by lipid film hydration method, fully described previously 
(10). Ephemerally, 300 µmole Span 60 and cholesterol (70/30 
molar percent) was dissolved in 5 ml chloroform and the 
organic solvent was evaporated in a rotary evaporator 
(Heidolf, Germany) under reduced pressure at 65°C. The 
dried lipid film was put in a vacuum oven overnight for 
ensuring the trace organic solvent elimination. Zinc sulfate 
heptahydrate was dissolved in enough warm deionized water 
to form 2% w/v solution of Zn
2+
and then used for hydration of 
dried lipid form at 65°C for 30 min. Niosomal suspension was 
maintained at room temperature for 24 h to complete the 
process of lipid vesicular bilayers hydration (11). Final full-
hydrated niosomes were kept at refrigerator for further 
pharmaceutical studies; for clinical trial, the niosomal 
suspensions were used during 6 months after preparation.  
 
Evaluation of physical properties of niosomes 
The vesicular aggregation, apparent view/type of 
niosomes, and probable separation of Span 60 or cholesterol 
from lipid bilayers were evaluated by optical microscopy 
(Hfxdx, Nikon, Japan) equipped by a picture transferring loop 
and related software (Dino Capture 20, Taiwan) to get some 
photomicrographs. 
Size analysis of non-ionic surfactant vesicles (NSVs) was 
carried out by using static laser light diffraction method 
(Malvern Instruments, Master Sizer 2000E, UK). 
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Samples were stored in glass vials for 3 months and were 
withdrawn at regular time intervals (1 week and 3, 6 months) 
and niosomal size measurement was done as a physical 
stability indicator. 
Multilamellar vesicles (MLVs) were formed as depicted 
in Fig. 1. Mean volume diameter of Span 60 niosomes was 
6.84±0.21 µm, 48 h after preparation. Size distribution curves 
of prepared MLVs (Fig. 2) showed high physical stability of 
niosomes. 
 
 
 
 
 
 
 
 
Fig1. Micrograph (40×10 magnifications) of zinc sulfate niosomal formulation composed of Span 60/cholesterol (70/30 molar percent); Scale bar = 
5µm. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. Size distribution and physical stability of zinc sulfate niosomal formulation composed of Span 60/cholesterol (70/30 molar percent) during 6 
months storage at 4-8°C. 
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Clinical study design and performance 
This is a double-blind randomized clinical trial that 
enrolled 60 patients with diagnosis of verruca vulgaris 
(common wart) in Afzalipour hospital and dermatologic 
clinics in Kerman. Exclusion criteria included lesions located 
on face, genitalia and periungual areas, patients’ ages less than 
12 months, immune suppression, pregnant or lactating women 
and those who had received any kind of treatments in 
advance.  
After signing the informed consent form, patients were 
divided (simple randomization) in 2 groups by Mini Tab 16 
(Mini Tab Inc.). Firstly, demographic features such as age, sex 
and site of the lesions were recorded. In each patient, one 
lesion with largest diameter (at least 6 millimeter) was 
evaluated. Then, we treated patients in groups A and B with 
2% niosomal zinc sulfate and placebo cream twice a day, 
respectively. Both groups underwent two-double freeze-thaw 
cycle cryotherapy with liquid nitrogen every other week by 
cotton swab until a 2 millimeter white halo in the periphery of 
the lesion appeared. Duration of each cycle of cryotherapy 
depends on site and size of the lesion that varied between 5 to 
30 seconds. Treatment was performed for a maximum of 3 
months or until total clearance of the lesions, whichever 
occurred first. Patients were evaluated every two weeks, at 
baseline, 2, 4, 6, 8, 10, 12 weeks of treatment for treatment 
efficacy and possible adverse effects (pain, pruritus, hypo and 
hyper pigmentation, blister or scar formation). The efficacy 
was evaluated based on a reduction in lesion size. We 
measured size of the lesions by a standard scaled ruler in 
largest diameter. Patients were followed up at 6 weeks after 
the end of the treatment for evaluation of probable recurrence. 
 
Statistical analysis 
We used mean ± standard deviation and frequency for 
descriptive analysis, and chi-square test for evaluation of 
efficacy and side effects. In order to compare the 2 groups, we 
used” t test”. We used SPSS version 20 for statistical analysis. 
P. value less than 0.05 was considered significant. 
 
Results 
Thirty patients in each group including 51.66% males and 
48.33% females were enrolled into the study. Most of the 
lesions were located in upper limb (55%). Table 1 shows 
demographic features of the patients and site of involvement. 
Difference between response rates in 2 groups was not 
significant after 7 sessions of treatment except in the sixth 
session (10 weeks after the start of treatment). Table 2 shows 
mean size of the lesions in both treatment groups. 
Mean number of the required sessions for complete 
remission was 4.5±1.38 in group A and 5.36±0.88 in group B 
with a significant difference (p=0.005). Complete remission 
was observed in 60% of group A compared with 43.3% in 
group B (p=0.30). Percentage of complete remission between 
the two treatment groups was significantly different (Table 3). 
Adverse effects such as pain, pruritus and hyper 
pigmentation were most prevalent in group A, but blister 
formation and hypopigmantation in group B (Table 4). 
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Table 1. Demographic features of the patients and location of involvement  
Variables Case group Control group Total P. value 
Sex 
Male 19(63.3%) 12(40%) 31(51.7%) 
0.07 
Female 11(36.7%) 18(60%) 29(48.3%) 
Mean age(years) 28.8±8.84 26.70±9.77  0.71 
Site of the 
involvement 
Upper limb 17(56.7%) 16(53.3%) 33(55%) 
0.58 Lower limb 12(40%) 11(36.7%) 23(38.3%) 
Other locations 1(3.3%) 3(10%) 4(6.7%) 
 
Table 2. Size of the lesions (mean ±SD) during the sessions of the treatment in both groups 
 Size of the lesion (mm)  
Treatment sessions  Case group   Control group  p. value 
Basic 8.75±3.50 9.15±3.70 0.66 
2Weeks 8.36±3.55 8.73±3.72 0.69 
4Weeks 6.40±2.94 7.36±3.36 0.24 
6Weeks 4.80±2.78 5.90±3.03 0.14 
8Weeks 3.03±2.84 4.30±2.81 0.08 
10Weeks 1.80±0.40 3.06±0.43 0.03 
12weeks 1.13±0.30 1.73±0.39 0.23 
 
Table 3. Complete remission in two treatment groups during the treatment 
Treatment sessions 
Case group 
N (%) 
Control group 
N (%) 
P value 
6 weeks 1(3.3) 0(0) 0.31 
8 weeks 10(33.3) 2(6.7) 0.01 
10 weeks 16(53.3) 4(12.3) 0.001 
12 weeks 18(60) 13(43.3) 0.19 
 
Table 4. prevalence of adverse effects in both treatment groups 
Adverse effects 
Case group 
N (%) 
Control group 
N (%) 
Total 
N (%) 
P. value 
Pain 26(52) 24(48) 50 0.49 
Blister 15(46.9) 17(53.1) 32 0.60 
Pruritous 10(71.4) 4(28.6) 14 0.006 
Hyperpigmentation 8(57.1) 8(42.9) 16 0.54 
hypopigmentation 12(46.2) 14(53.8) 26 0.60 
 
Discussion 
Zinc is an immune system regulator and its deficiency 
may lead to lymphocyte T dysfunction. Zinc can induce 
stimulation of cytotoxic T lymphocytes that may lead to 
clearance of warts by increased production of interferon α. 
Oral zinc sulfate supplements have a significant role in the 
treatment of refractory lesions in patients with low serum level 
of zinc. But its prescription in patients with normal serum 
level of zinc has no benefit in comparison with placebo. Also, 
oral zinc sulfate can lead to gastrointestinal adverse effects 
such as vomiting, nausea and abdominal pain. Topical 
formulation of zinc can lead to clearance of infected 
keratinocytes with HPV by stimulation of immune system 
through induction of inflammation and necrosis. Topical zinc 
sulfate may cause pain, tenderness, swelling and erythema at 
the location of application and may lead to scar formation (12-
15). 
Niosomal drug delivery system has more stability and skin 
absorption that can lead to slow release of drugs, lower side 
effects and higher efficacy. In this study the rate of complete 
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response with combination of niosomal zinc sulfate plus 
cryotherapy was 60% in comparison with combined 
cryotherapy and placebo that was 43.3%, but the difference 
was not statistically significant. Also, clearance percentage 
after 8 weeks of treatment was significantly higher in 
niosomal group than control group (8,9). 
In one study by Sharquie and colleagues in 2002, injection 
of 2% zinc sulfate was evaluated with complete response rate 
of 98.2%. 80.92% of the patients had complete clearance after 
only one treatment session. Although this result was better 
than our findings, but adverse effects including tenderness, 
swelling, erythema and hyper pigmentation was observed in 
100% of the patients in Sharquie’s study. Also, because of 
possible risk of necrosis in acral regions, intralesional form of 
the drug cannot be used (16). 
In another study by Sharquie and colleagues in 2007, 10% 
and 5% zinc sulfate were implicated for plane warts for 4 
weeks with response rates of 85.7% and 42.8%, respectively. 
However, response rate for verruca vulgaris was very low 
(11%, 5%, respectively). In our study the response rate for 
common wart was superior to the study conducted by Shaquie 
and colleagues (17). This can be due to combined treatment 
with cryotherapy, longer duration of treatment and also better 
absorption of niosomal forms of zinc. 
In another study by Khatter in 2007, complete clearance 
with 20% zinc oxide ointment was 50%. Despite higher 
percentage of zinc in Khatter’s study compared to our research 
(20% in their study vs. 2% in our study), complete response 
was lower in their study. In our study combination therapy 
was used with cryotherapy, while in Khatter’s study 
mechanical keratolytic method (stone) was applied as 
combination (18).  
In our research, mean count of sessions for case and 
control groups were 4.5±1.38 and 5.36±0.88, respectively that 
was statistically significant. In contrast, in khattar’s study 
differences between mean numbers of the sessions were not 
significant and it was longer than our study. Also, in our study 
all of the treated lesions were vulgaris type, but, in khattar’s 
study 32% of the lesions were plane wart and because of 
lower thickness, better response to treatment was dominant 
(18). 
In our study, addition of niosomal zinc sulfate to 
cryotherapy did not lead to a significant increase in adverse 
effects. In Khattar’s study (18), swelling was reported 
predominantly in zinc sulfate group. In our study in 
comparison with Khattar’s study, we observed more side 
effects including pruritus, pain and hyperpigmentation. Of 
course this finding is predictable in combined treatment of 
niosomal zinc sulfate with cryotherapy. 
So, niosomal zinc sulfate combined with cryotherapy led 
to faster improvement in comparison with other treatment 
modalities such as cryotherapy, keratolytic compound of 
salicylic acid as well as lactic acid and combined conventional 
zinc sulfate with mechanical keratolytic methods (18). 
 
Conclusion 
According to our findings, addition of niosomal zinc 
sulfate to cryotherapy can lead to rapid remission of the 
lesions and higher percentage of clearance without a 
significant increase in adverse effects. We recommend another 
study to evaluate the efficacy of treatment with niosomal zinc 
sulfate as monotherapy with conventional formulation. 
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